Search

Your search keyword '"Kabran, Mathieu"' showing total 9 results
Start Over Author "Kabran, Mathieu"
9 results on '"Kabran, Mathieu"'

2. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial

Author

Badje, Anani, Moh, Raoul, Gabillard, Delphine, Guéhi, Calixte, Kabran, Mathieu, Ntakpé, Jean-Baptiste, Le Carrou, Jérôme, Kouame, Gérard-Menan, Ouattara, Eric, Messou, Eugène, Anzian, Amani, Minga, Albert, Gnokoro, Joachim, Gouesse, Patrice, Emieme, Arlette, Toni, Thomas-d'Aquin, Rabe, Cyprien, Sidibé, Baba, Nzunetu, Gustave, Dohoun, Lambert, Abo, Yao, Kamagate, Synali, Amon, Solange, Kouame, Amadou-Barenson, Koua, Aboli, Kouamé, Emmanuel, Daligou, Marcelle, Hawerlander, Denise, Ackoundzé, Simplice, Koule, Serge, Séri, Jonas, Ani, Alex, Dembélé, Fassery, Koné, Fatoumata, Oyebi, Mykayila, Mbakop, Nathalie, Makaila, Oyewole, Babatunde, Carolle, Babatunde, Nathaniel, Bleoué, Gisèle, Tchoutedjem, Mireille, Kouadio, Alain-Claude, Sena, Ghislaine, Yededji, Sahinou-Yediga, Karcher, Sophie, Rouzioux, Christine, Kouame, Abo, Assi, Rodrigue, Bakayoko, Alima, Domoua, Serge-K., Deschamps, Nina, Aka, Kakou, N'Dri-Yoman, Thérèse, Salamon, Roger, Journot, Valérie, Ahibo, Hughes, Ouassa, Timothée, Ménan, Hervé, Inwoley, André, Ndja, Ben-Ahoussi, Adou, Blandine, Kanga, Constance, Aoussi, Eba, Bissagnene, Emmanuel, Ba-Gomis, Olivier, Zike, Yves-Alain, Akakpo, Claude, Sassan-Morokro, Madeleine, Mobio, Max, Doféré, Bamba, Mesmin, Koman, Attia, Alain, Mahassadi, Alassane, Horo, Apollinaire, Oussou, Armel, Chaix, Marie-Laure, Peytavin, Gilles, Koné, Mariatou, N'Guessan, Kouamé, Fassassi, Raïmi, Niangoran, Serge, Desgrées-du-Loû, Annabel, Lert, France, Dray Spira, Rosemary, Jean, Kevin, Konan, Romuald, Bohoussou, Franck, Yao-Yapi, Cyril, N'guessan-Koffi, Larissa, Siloué, Bertine, Cissé, Adoulaye, Aboua, Adrienne, Konan, Sylvie, Kouamé, Antoine, N'Chot, Celestin, Amani, Elvis, Clouet, Gwenaëlle, Debono, Bruno, Chêne, Geneviève, Dosso, Mireille, Girard, Pierre-Marie, Jarlier, Vincent, Masumbuko, Jean-Marie, Perronne, Christian, Sow, Papa-Salif, Danel, Christine, Eholié, Serge-Paul, Anglaret, Xavier, Carrou, Jérôme Le, Kouame, Gérard M, Yao, Abo, Domoua, Serge K, Menan, Hervé, and Eholié, Serge P

Published
2017
Full Text
View/download PDF

7. Quantiferon-TB Gold: Performance for Ruling out Active Tuberculosis in HIV-Infected Adults with High CD4 Count in Côte d'Ivoire, West Africa

Author

Danel, Christine, primary, Kabran, Mathieu, additional, Inwoley, André, additional, Badje, Anani, additional, Herrmann, Jean Louis, additional, Moh, Raoul, additional, Lecarrou, Jérôme, additional, Gabillard, Delphine, additional, Ntakpe, Jean Baptiste, additional, Deschamps, Nina, additional, Ouattara, Eric, additional, Perronne, Christian, additional, Eholie, Serge, additional, and Anglaret, Xavier, additional

Published
2014
Full Text
View/download PDF

8. Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa

Author

Wandeler, Gilles, Coffie, Patrick A, Ekouevi, Didier K, Dabis, François, Gottlieb, Geoffrey S, Bado, Guillaume, Eholie, Serge P, Kabran, Mathieu, Minta, Daouda K, and Tchounga, Boris K

Subjects
virus diseases, 610 Medicine & health, 360 Social problems & social services, 3. Good health
Abstract

BACKGROUND In West Africa where HIV-1 and HIV-2 co-circulate, the co-infection with hepatitis B virus (HBV) and hepatitis Delta virus (HDV) is not well described. This study aimed at estimating the prevalence of HBV and HBV/HDV co-infection according to HIV types and risk factors for HBV infection among West African HIV-infected patients. METHOD A cross-sectional survey was conducted within the IeDEA West Africa cohort from March to December 2012 in Côte d'Ivoire (three sites), Burkina Faso and Mali (one site each). All HIV-infected adult patients on antiretroviral therapy (ART) or not who attended one of the participating HIV clinics during the study period and agreed to participate were included. Blood samples were collected and re-tested for HIV type discrimination, HBV and HDV serology as well as HBV viral load. Logistic regression was used to identify risk factors for HBV infection. RESULTS A total of 791 patients were included: 192 HIV-1, 447 HIV-2 and 152 HIV-1&2 dually reactive. At time of sampling, 555 (70.2%) were on ART and median CD4+ cell count was 472/mm(3) (inter-quartile range [IQR]: IQR: 294-644). Sixty-seven (8.5%, 95% CI 6.6-10.6) patients were HBsAg positive without any difference according to HIV type (7.9% in HIV-1, 7.2% in HIV-1&2 dually reactive and 9.4% in HIV-2; p = 0.61). In multivariate logistic analysis, age ≤ 30 years old (adjusted odds ratio [aOR] 5.00, 95% CI 1.96-12.76), age between 31 and 49 years old (aOR 1.78, 95% CI 1.00-2.21) and male gender (aOR 2.15, 95% CI 1.25-3.69) were associated with HBsAg positivity. HBV DNA testing was performed in 36 patients with blood sample available (25 on ART) and 8 (22.2%) had detectable HBV DNA. Among the HBsAg-positive individuals, 14.9% (95% CI 7.4-25.7) were also positive for anti-HDV antibody without any difference according to HIV type (28.6% in HIV-1, 14.3% in HIV-2 and 0.0% in HIV-1&2 dually reactive; p = 0.15). CONCLUSION HBV and HBV/HDV co-infection are common in West Africa, irrespective of HIV type. Therefore, screening for both viruses should be systematically performed to allow a better management of HIV-infected patients. Follow-up studies are necessary to determine the impact of these two viruses on HIV infection.

9. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

Author

Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpé JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouamé A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibé B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, Kouame AB, Koua A, Kouamé E, Ndri Y, Ba-Gomis O, Daligou M, Ackoundzé S, Hawerlander D, Ani A, Dembélé F, Koné F, Guéhi C, Kanga C, Koule S, Séri J, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatounde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Assi R, Bakayoko A, Mahassadi A, Attia A, Oussou A, Mobio M, Bamba D, Koman M, Horo A, Deschamps N, Chenal H, Sassan-Morokro M, Konate S, Aka K, Aoussi E, Journot V, Nchot C, Karcher S, Chaix ML, Rouzioux C, Sow PS, Perronne C, Girard PM, Menan H, Bissagnene E, Kadio A, Ettiegne-Traore V, Moh-Semdé C, Kouame A, Massumbuko JM, Chêne G, Dosso M, Domoua SK, N'Dri-Yoman T, Salamon R, Eholié SP, and Anglaret X

Subjects
Adult, Anti-Retroviral Agents adverse effects, Antitubercular Agents adverse effects, Asymptomatic Diseases, CD4 Lymphocyte Count, Cote d'Ivoire, Female, Follow-Up Studies, HIV Infections immunology, Humans, Isoniazid adverse effects, Male, Middle Aged, RNA, Viral analysis, Time-to-Treatment, Viral Load, AIDS-Related Opportunistic Infections prevention & control, Anti-Retroviral Agents therapeutic use, Antitubercular Agents therapeutic use, HIV Infections drug therapy, HIV-1 genetics, HIV-1 isolation & purification, Isoniazid therapeutic use, Tuberculosis prevention & control
Abstract

Background: In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)-associated tuberculosis is high. We conducted a trial with a 2-by-2 factorial design to assess the benefits of early antiretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-infected adults with high CD4+ cell counts in Ivory Coast., Methods: We included participants who had HIV type 1 infection and a CD4+ count of less than 800 cells per cubic millimeter and who met no criteria for starting ART according to World Health Organization (WHO) guidelines. Participants were randomly assigned to one of four treatment groups: deferred ART (ART initiation according to WHO criteria), deferred ART plus IPT, early ART (immediate ART initiation), or early ART plus IPT. The primary end point was a composite of diseases included in the case definition of the acquired immunodeficiency syndrome (AIDS), non-AIDS-defining cancer, non-AIDS-defining invasive bacterial disease, or death from any cause at 30 months. We used Cox proportional models to compare outcomes between the deferred-ART and early-ART strategies and between the IPT and no-IPT strategies., Results: A total of 2056 patients (41% with a baseline CD4+ count of ≥500 cells per cubic millimeter) were followed for 4757 patient-years. A total of 204 primary end-point events were observed (3.8 events per 100 person-years; 95% confidence interval [CI], 3.3 to 4.4), including 68 in patients with a baseline CD4+ count of at least 500 cells per cubic millimeter (3.2 events per 100 person-years; 95% CI, 2.4 to 4.0). Tuberculosis and invasive bacterial diseases accounted for 42% and 27% of primary end-point events, respectively. The risk of death or severe HIV-related illness was lower with early ART than with deferred ART (adjusted hazard ratio, 0.56; 95% CI, 0.41 to 0.76; adjusted hazard ratio among patients with a baseline CD4+ count of ≥500 cells per cubic millimeter, 0.56; 95% CI, 0.33 to 0.94) and lower with IPT than with no IPT (adjusted hazard ratio, 0.65; 95% CI, 0.48 to 0.88; adjusted hazard ratio among patients with a baseline CD4+ count of ≥500 cells per cubic millimeter, 0.61; 95% CI, 0.36 to 1.01). The 30-month probability of grade 3 or 4 adverse events did not differ significantly among the strategies., Conclusions: In this African country, immediate ART and 6 months of IPT independently led to lower rates of severe illness than did deferred ART and no IPT, both overall and among patients with CD4+ counts of at least 500 cells per cubic millimeter. (Funded by the French National Agency for Research on AIDS and Viral Hepatitis; TEMPRANO ANRS 12136 ClinicalTrials.gov number, NCT00495651.).

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results